Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Toyama Chemical Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Toyama Chemical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Toyama Chemical Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Toyama Chemical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Toyama Chemical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Toyama Chemical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Toyama Chemical Co., Ltd.'s pipeline products Reasons to buy - Evaluate Toyama Chemical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Toyama Chemical Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Toyama Chemical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Toyama Chemical Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Toyama Chemical Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Toyama Chemical Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Toyama Chemical Co., Ltd. Snapshot 5 Toyama Chemical Co., Ltd. Overview 5 Key Information 5 Key Facts 5 Toyama Chemical Co., Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Toyama Chemical Co., Ltd. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Toyama Chemical Co., Ltd. - Pipeline Products Glance 12 Toyama Chemical Co., Ltd. - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 Toyama Chemical Co., Ltd. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Toyama Chemical Co., Ltd. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Toyama Chemical Co., Ltd. - Drug Profiles 17 garenoxacin mesylate 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 favipiravir 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ozenoxacin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 T-5224 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 T-817MA 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 solithromycin 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 T-2307 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 T-1106 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Toyama Chemical Co., Ltd. - Pipeline Analysis 30 Toyama Chemical Co., Ltd. - Pipeline Products by Target 30 Toyama Chemical Co., Ltd. - Pipeline Products by Route of Administration 31 Toyama Chemical Co., Ltd. - Pipeline Products by Molecule Type 32 Toyama Chemical Co., Ltd. - Pipeline Products by Mechanism of Action 33 Toyama Chemical Co., Ltd. - Recent Pipeline Updates 34 Toyama Chemical Co., Ltd. - Dormant Projects 44 Toyama Chemical Co., Ltd. - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Toyama Chemical Co., Ltd., Key Information 5 Toyama Chemical Co., Ltd., Key Facts 5 Toyama Chemical Co., Ltd. - Pipeline by Indication, 2014 7 Toyama Chemical Co., Ltd. - Pipeline by Stage of Development, 2014 8 Toyama Chemical Co., Ltd. - Monotherapy Products in Pipeline, 2014 9 Toyama Chemical Co., Ltd. - Partnered Products in Pipeline, 2014 10 Toyama Chemical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 11 Toyama Chemical Co., Ltd. - Pre-Registration, 2014 12 Toyama Chemical Co., Ltd. - Phase III, 2014 13 Toyama Chemical Co., Ltd. - Phase II, 2014 14 Toyama Chemical Co., Ltd. - Phase I, 2014 15 Toyama Chemical Co., Ltd. - Preclinical, 2014 16 Toyama Chemical Co., Ltd. - Pipeline by Target, 2014 30 Toyama Chemical Co., Ltd. - Pipeline by Route of Administration, 2014 31 Toyama Chemical Co., Ltd. - Pipeline by Molecule Type, 2014 32 Toyama Chemical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 33 Toyama Chemical Co., Ltd. - Recent Pipeline Updates, 2014 34 Toyama Chemical Co., Ltd. - Dormant Developmental Projects,2014 44 Toyama Chemical Co., Ltd., Other Locations 45 Toyama Chemical Co., Ltd., Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.